EMERYVILLE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following...
EMERYVILLE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) (“XOMA Royalty” or the “Company”), a biotechnology royalty aggregator playing a distinctive role...
NEW YORK , Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of XOMA Royalty Corporation ("Xoma" or the "Company") (NASDAQ: XOMA). Such investors are advised...
NEW YORK , Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of XOMA Royalty Corporation ("Xoma" or the "Company") (NASDAQ: XOMA). Such investors are advised...
EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA) announced today its Chief Financial Officer, Thomas Burns, will be stepping down from...
NEW YORK , Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of XOMA Royalty Corporation ("Xoma" or the "Company") (NASDAQ: XOMA). Such investors are advised...
NEW YORK , Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of XOMA Royalty Corporation ("Xoma" or the "Company") (NASDAQ: XOMA). Such investors are advised...
– Takeda regains a majority of XOMA Royalty’s royalty interest in mezagitamab (TAK-079) – – XOMA Royalty will be entitled to payments based on a share of milestones and royalties associated with...
EMERYVILLE, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA), the biotech royalty aggregator, today announced its Board of Directors has authorized the following cash...
- Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio’s collaboration with Moderna - - Generation Bio’s cell-targeted lipid nanoparticles (ctLNP)...